Bromocriptine Mesylate Patent Expiration
Bromocriptine Mesylate is Used for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. It was first introduced by Esjay Pharma Llc
Bromocriptine Mesylate Patents
Given below is the list of patents protecting Bromocriptine Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Cycloset | US10688094 | Bromocriptine formulations | Apr 30, 2032 | Veroscience |
| Cycloset | US11000522 | Bromocriptine formulations | Apr 30, 2032 | Veroscience |
| Cycloset | US8431155 | Bromocriptine formulations | Apr 30, 2032 | Veroscience |
| Cycloset | US8613947 | Bromocriptine formulations | Apr 30, 2032 | Veroscience |
| Cycloset | US9192576 | Bromocriptine formulations | Apr 30, 2032 | Veroscience |
| Cycloset | US9522117 | Bromocriptine formulations | Apr 30, 2032 | Veroscience |
| Cycloset | US9700555 | Bromocriptine formulations | Apr 30, 2032 | Veroscience |
| Cycloset | US9993474 | Bromocriptine formulations | Apr 30, 2032 | Veroscience |
| Cycloset | US10688155 | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders | Jun 07, 2030 | Veroscience |
| Cycloset | US8877708 | Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders | Jun 07, 2030 | Veroscience |
| Cycloset | US9352025 | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders | Jun 07, 2030 | Veroscience |
| Cycloset | US9895422 | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders | Jun 07, 2030 | Veroscience |
| Cycloset | US7888310 | Methods of identifying responders to dopamine agonist therapy |
Jul 25, 2023
(Expired) | Veroscience |
| Cycloset | US8137992 | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
Jul 25, 2023
(Expired) | Veroscience |
| Cycloset | US8137993 | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
Jul 25, 2023
(Expired) | Veroscience |
| Cycloset | US8137994 | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
Jul 25, 2023
(Expired) | Veroscience |
| Cycloset | US5716957 | Method for modifying and resetting the bloodstream prolactin levels of a human subject |
Feb 10, 2015
(Expired) | Veroscience |
| Cycloset | US5679685 | Accelerated release composition containing bromocriptine |
Oct 21, 2014
(Expired) | Veroscience |
| Cycloset | US5468755 | Therapeutic process for the treatment of the pathologies of Type II diabetes |
Nov 21, 2012
(Expired) | Veroscience |
| Cycloset | US5756513 | Therapeutic process for the treatment of the pathologies of type II diabetes |
Nov 21, 2012
(Expired) | Veroscience |
| Cycloset | US5866584 | Therapeutic process for the treatment of the pathologies of type II diabetes |
Nov 21, 2012
(Expired) | Veroscience |
Bromocriptine Mesylate's Family Patents
Explore Our Curated Drug Screens
Bromocriptine Mesylate Generic API Manufacturers
Several generic applications have been filed for Bromocriptine Mesylate. The first generic version for Bromocriptine Mesylate was by Sandoz Inc and was approved on Jan 13, 1998. And the latest generic version is by Padagis Us Llc and was approved on Oct 1, 2008.
Given below is the list of companies who have filed for Bromocriptine Mesylate generic, along with the locations of their manufacturing plants worldwide.
1. AUROBINDO PHARMA USA
Aurobindo Pharma Usa Inc has filed for 1 generic for Bromocriptine Mesylate. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 2.5MG BASE | tablet | Discontinued | ORAL | N/A | Sep 24, 2004 |
Manufacturing Plant Locations New
Aurobindo Pharma Usa's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma Usa as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
2. LEK PHARM
Lek Pharmaceutical And Chemical Co Dd has filed for 1 generic for Bromocriptine Mesylate. Given below are the details of the strengths of this generic introduced by Lek Pharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 5MG BASE | capsule | Discontinued | ORAL | N/A | Dec 10, 1998 |
Manufacturing Plant Locations New
Lek Pharm's manufacturing plants are situated in 1 country - Slovenia. Given below are the details of these plant locations as well as the firm names of Lek Pharm as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| Slovenia |
| |||
3. MYLAN
Mylan Pharmaceuticals Inc has filed for 1 generic for Bromocriptine Mesylate. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 5MG BASE
(reference standard) | capsule | Prescription | ORAL | AB | Apr 4, 2005 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
| Canada |
| |||||||||||||||||
| Ireland |
| |||||||||||||||||
4. PADAGIS US
Padagis Us Llc has filed for 1 generic for Bromocriptine Mesylate. Given below are the details of the strengths of this generic introduced by Padagis Us.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 2.5MG BASE
(reference standard) | tablet | Prescription | ORAL | AB | Oct 1, 2008 |
Manufacturing Plant Locations New
Padagis Us's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Padagis Us as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
5. SANDOZ
Sandoz Inc has filed for 1 generic for Bromocriptine Mesylate. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 2.5MG BASE | tablet | Prescription | ORAL | AB | Jan 13, 1998 |
Manufacturing Plant Locations New
Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| Austria |
| |||||
| United States |
| |||||
| Spain |
| |||||
| India |
| |||||
6. ZYDUS PHARMS USA INC
Zydus Pharmaceuticals Usa Inc has filed for 1 generic for Bromocriptine Mesylate. Given below are the details of the strengths of this generic introduced by Zydus Pharms Usa Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 5MG BASE | capsule | Prescription | ORAL | AB | Jul 30, 2008 |